Meridian Bioscience Inc. (VIVO) Updates FY15 Earnings Guidance
Meridian Bioscience Inc. (NASDAQ:VIVO) issued an update on its FY15 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.85-0.91 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.97, AnalystRatingsNetwork.com reports. The company issued revenue guidance of $193-200 million, compared to the consensus revenue estimate of $203.75 million.Meridian Bioscience also updated its FY14 guidance to $0.85-0.90 EPS.
Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 19.57 on Tuesday. Meridian Bioscience Inc. has a 1-year low of $19.14 and a 1-year high of $27.72. The stock has a 50-day moving average of $20.14 and a 200-day moving average of $20.67. The company has a market cap of $813.5 million and a price-to-earnings ratio of 23.09.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings data on Thursday, July 24th. The company reported $0.21 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.22 by $0.01. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $47.96 million. During the same quarter in the prior year, the company posted $0.24 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. On average, analysts predict that Meridian Bioscience Inc. will post $0.86 earnings per share for the current fiscal year.
Meridian Bioscience, Inc (NASDAQ:VIVO) is a fully-integrated life science company.